Vaxil BioTherapeutics

Vaxil Bio Ltd. is an immunotherapy biotech company based in Toronto, Canada, specializing in drug discovery and development using signal peptides to target infectious diseases and cancer. The company's leading product, ImMucin, has successfully completed a Phase I/II clinical trial for treating multiple myeloma. Vaxil is also working on a tuberculosis vaccine and a coronavirus vaccine. Additionally, the company has established a collaboration with The Tel Aviv Sourasky Medical Center to develop a peptide vaccine against COVID-19 and has a research agreement with the U.S. Army Medical Research Institute of Infectious Diseases to test its CorVax vaccine in mice. Founded in 2006, Vaxil is committed to advancing innovative therapeutic and preventive vaccines through its proprietary VaxHit technology.